TRAIL及其在白血病治疗中的研究进展

肿瘤坏死因子相关凋亡诱导配体(TRAIL)是近几年研究较热的抗肿瘤新型生物制剂,通过其死亡受体诱导肿瘤细胞凋亡,而对正常细胞无毒性,且与化疗药物具有协同性,但也存在抵抗机制.该文就TRAIL的生物学特点及其受体、TRAIL诱导肿瘤细胞凋亡的机制以及TRAIL在白血病治疗中的进展作一综述.

Progress of TRAIL and its application in leukemia therapy

Tumor necrosis factor-related apoptosis-inducing ligand(TRAIL) is a new anti-tumor biological agents which is very hot in recent years through its death receptor-induced apoptosis of tumor cells,and non-toxic to normal cells,and has synergy with the chemotherapy drug,but there is also resistance mechanisms.This article will review the biological characteristics of TRAIL and its receptors,TRAIL-induced apoptosis of tumor cells,as well as the mechanism of TRAIL in leukemia in the progress of treatment.